frican horse sickness (AHS) was first identified as a disease in horses in South Africa in 1891 and the viral nature of its etiological agent, African horse sickness virus (AHSV), was established in 1900 (1) . The virus is transmitted by hematophagous Culicoides midges (2, 3) and can cause mortalities in up to 95% of fully susceptible horses. AHS is endemic in most of sub-Saharan Africa, occurs sporadically in North Africa, Mediterranean countries, and the Middle East, and a few outbreaks have been recorded in India and Pakistan. AHSV is a double-stranded RNA (dsRNA) virus with ten genome segments that belongs to the genus Orbivirus, family Reoviridae. Nine serotypes of the virus have been distinguished (4, 5) .
Currently, the AHSV reference strains of the Office International des Epizooties (OIE) used at the ARC-Onderstepoort Veterinary Institute (OVI), South Africa, consist of at least one pathogenic isolate of each serotype from AHS outbreaks between 1955 and 1963 (6). These virulent reference viruses are used as challenge viruses during vaccine trials. Tissue culture-adapted progeny of these viruses and guinea pig sera raised against them are widely used as diagnostic reagents for serotyping AHSV isolates and to determine the immunity status of horses before and after vaccination (6) .
The histories of the viruses used in this study (Table 1) were compiled from ARC-OVI specimen collection records from 1958 to 2009, records of vaccine trials in horses, personal communication with B. J. Erasmus, and the literature (4, (6) (7) (8) . For this project, the virulent OIE reference strains and neurotropic vaccines were propagated by intracerebral injection of 2-day-old Swiss white mice, and the recent field isolates of AHSV were propagated in either BHK-21 or Vero cells. Extraction and purification of dsRNA, sequence-independent genome amplification, Roche 454 sequencing, and de novo sequence assembly were done as described previously (9) .
Here we announce the first complete consensus genome sequence of each of the nine original pathogenic OIE reference strains of AHSV prior to the adaptation of the viruses to cell culture (10), some of the neurotropic AHSV vaccine strains (4, 11) , and recent isolates of all nine AHSV serotypes made at the ARC-OVI from 1998 to 2009 (Table 1) . In all, we sequenced 10 OIE reference strains (including HS2/75 used for attenuation of AHSV6), 5 neurotropic historic vaccine strains, and 12 recent field isolates. This sequence data set of 27 AHSV strains is the first representing all nine AHSV serotypes from both historical and recent isolates collected over a long period of 76 years (1933 to 2009). These genome sequence sets should be useful for comparison with sequences from live vaccine strains that were derived from them and published sequences from cloned genome segments that are mostly incorrect due to cloning biases, such as the genome segment 2 (VP2) sequence set of all nine AHSV serotypes (12) . The consensus genome sequence data set of this announcement has already allowed the development of group-and serotype-specific real-time RT-PCRs (13) and, more importantly, has been used to rescue AHSVs of all nine serotypes by reverse genetics, which verifies their correctness (14) .
Nucleotide sequence accession numbers. The nucleotide sequences have been deposited in GenBank under the accession numbers listed in Table 1 .
